

PLEASE CLICK ON THE PAGE NUMBER TO MOVE TO THE RELEVANT PAGE.

KEY HIGHLIGHTS

Strategy

Alpha Picks: Underperformance In Aug 23

Our picks: MYOR, BSDE, CTRA, HMSP, BBNI, SMGR and MAPI.

Page 2

TRADERS' CORNER

Bumi Resources (BUMI IJ): Technical BUY

Aneka Tambang (ANTM IJ): Technical BUY

Page 8

REGIONAL MARKET

Market	Close	+ / -	Chg (%)
MSCI Indonesia	7,636.6	35.2	0.5
MSCI Asia-Ex Japan	625.5	3.1	0.5
KLCI	1,463.4	11.5	0.8
FSSTI	3,233.3	-	-
SET	1,561.5	(4.4)	(0.3)
Hang Seng	18,382.1	-	-
Nikkei	32,710.6	91.3	0.3
Shanghai Comp	3,133.2	13.4	0.4
Dow Jones	34,837.7	115.8	0.3

Source: Bloomberg

INDONESIA STOCK EXCHANGE

	Level	+ / -	Chg (%)
Index	6,977.7	24.4	0.4
LQ-45	967.0	4.7	0.5
Value (US\$m)	581.8	(352.6)	(37.7)

FOREIGN TRADE IN IDX

Net (US\$m)	Buy	Sell	Total (%)
33.1	169.7	136.6	26.3

TOP VOLUME

Company	Price (Rp)	Chg (%)	Volume ('000)
GoTo Gojek Tokopedia	95	(1.0)	1,217,262
Medco Energi	1,290	20.6	586,830
Bumi Resources Minerals	200	2.6	418,434
Bumi Resources	141	2.2	343,309
Barito Pacific	1,200	12.1	207,949

TOP GAINERS

Company	Price (Rp)	Chg (%)	Volume ('000)
Medco Energi	1,290	20.6	586,830
Barito Pacific	1,200	12.1	207,949
AKR Corporindo	1,495	6.8	119,685
Amman Mineral	4,750	4.9	84,973
Elang Mahkota	590	3.5	45,003

TOP LOSERS

Company	Price (Rp)	Chg (%)	Volume ('000)
Golden Energy	6,525	(10.3)	1,857
Dian Swastatika	48,000	(5.0)	1,200
Tower Bersama	2,030	(3.3)	7,433
Bank Mega	5,250	(2.8)	2
Dayamitra Telekomunikasi	730	(2.7)	57,414

COMMODITY TREND

	1 Sep 23 Closing	Chg (%) 1-day	Chg (%) 1-mth
Forex (Rp/US\$)	15,242	0.1	0.5
Crude Oil NYMEX (US\$/bbl)	85.55	2.3	3.3
Coal Fut Newc (US\$/tonne)	156.25	0.2	n.a.
Nickel 3M LME	21,085	3.9	(1.1)
Tin 3M LME	25,806	1.6	(6.8)
Gold SPOT (US\$/oz)	1,940	(0.2)	(0.1)
CPO Fut Msia (MYR/tonne)	3,910	1.3	3.4

Source: Bloomberg, UOB Kay Hian

STRATEGY – INDONESIA

Alpha Picks: Underperformance In Aug 23

Our portfolio declined by an average of 1.9% in Aug 23 compared with the JCI's return of -0.7%. Our short idea ADRO delivered a 9.8% appreciation, working against our view. BSDE declined 5.2% followed by HMSP which fell 4.3%. Other losers were SMGR (-3.5%) and MAPI (-3.3%). Gainers were MYOR (+7.3%), BBNI (+2.4%) and CTRA (+1.2%). We dropped ADRO as our analyst has upgraded the stock to BUY. Our picks: MYOR, BSDE, CTRA, HMSP, BBNI, SMGR and MAPI.

WHAT'S NEW

- **Our portfolio underperformed again in Aug 23.** Our portfolio declined by an average of 1.9% in Aug 23, underperforming the JCI which declined by only 0.7%. The biggest loser was our short idea on ADRO which delivered a 9.8% appreciation. BSDE dropped by 5.2%, HMSP dropped by 4.3%, SMGR declined by 3.5% and MAPI declined by 3.3%. Gainers are MYOR (+7.3%), BBNI (+2.4%) and CTRA (+1.2%).
- **Drop ADRO.** We drop ADRO from our selection of short ideas as our analyst has upgraded it to BUY.
- **MAPI is the top performer in our portfolio.** We continue to like MAPI as it is entering new markets such as Cambodia, penetrating existing markets such as Vietnam and the Philippines and acquiring new brands such as Footlocker.

ANALYSTS' ALPHA* PICKS

Analyst	Company	Rec	Performance [#]	Catalyst
Posmarito Pakpahan	Bank Negara Indonesia	BUY	-2.1%	Loan growth to accelerate in 2H23
Stevanus Juanda	Mitra Adiperkasa	BUY	63.4%	Earnings surprise on the upside. Over 15% EPS growth for the next two years.
Limartha Adhiputra	Bumi Serpong Damai	BUY	-4.0%	Better 3Q23 marketing sales and NPAT achievement.
Limartha Adhiputra	Ciputra Development	BUY	14.5%	Better 3Q23 marketing sales and NPAT achievement.
Limartha Adhiputra	Semen Indonesia	BUY	-0.4%	Potentially stronger sales volume, margin expansion, and higher NPAT achievement in 2H23.
Stevanus Juanda	HM Sampoerna	BUY	-4.9%	Recovery in purchasing power, selling price increased, attractively priced at -1SD PE.
Stevanus Juanda	Mayora Indah	BUY	7.3%	ASP increase of 15% in 2022 and raw material cost drop will expand margin in 2023.
				Drop: ADRO

* Denotes a timeframe of 1-3 months and not UOB Kay Hian's usual 12-month investment horizon for stock recommendation

Share price change since stock was selected as Alpha Pick Source: UOB Kay Hian

KEY RECOMMENDATIONS

Ticker	Rec	Price 31 Aug-23 (Rp)	Target Price (Rp)	Potential Upside (%)
BBNI	BUY	9,175	11,200	22.1
SMGR	BUY	6,800	9,200	35.3
BSDE	BUY	1,135	1,420	25.1
MAPI	BUY	1,935	2,500	29.2
CTRA	BUY	1,140	1,300	14.0
HMSP	BUY	880	1,300	47.7
MYOR	BUY	2,620	3,000	14.5

Source: UOB Kay Hian

CHANGE IN SHARE PRICE

Company	Rec	Aug-23 (%)	To Date (%)
BBNI	BUY	2.4%	-2.1%
SMGR	BUY	-3.5%	-0.4%
BSDE	BUY	-5.2%	-4.0%
MAPI	BUY	-3.3%	63.4%
CTRA	BUY	1.2%	14.5%
HMSP	BUY	-4.3%	-4.9%
ADRO	HOLD	-9.8%	-9.8%
MYOR	BUY	7.3%	7.3%
JCI		-0.7%	
USD-IDR X-RATE		-1.0%	

Source: UOB Kay Hian

PORTFOLIO RETURN

	2022	1Q23	2Q23
JCI return	4.1%	-0.7%	-2.1%
Alpha Picks Return			
Price-weighted	8.9%	-0.5%	-0.1%
Market cap-weighted	9.7%	1.9%	-1.4%
Equal-weighted	6.6%	-0.1%	-0.5%

Assumptions for the 3 methodologies:

- 1) Price-weighted: Assuming the same number of shares for each stock, a higher share price will have a higher weighting.
- 2) Market cap-weighted: Weighting is based on the market cap at date of inclusion, a higher market cap will have a higher weighting.
- 3) Equal-weighted: Assuming the same investment amount for each stock, every stock will have the same weighting.

Source: UOB Kay Hian

ANALYST(S)

Indonesia Research Team

+6221 2993 3845

researchindonesia@uobkayhian.com

VALUATION

Company	Ticker	Rec	Price 31-Aug-23 (Rp)	Target Price (Rp)	Potential Upside (%)	Market Cap (US\$m)	3M Avg Turnover (US\$m)	PE 2023F	2024F	P/B 2023F	2024F	ROE 2023F	Div. Yield 2023F	Net Gearing
Bank Negara Indonesia	BBNI	BUY	9,175	11,200	22.1	11,236	16.8	7.9	6.9	1.1	1.0	15	(74)	(74)
Semen Indonesia	SMGR	BUY	6,800	9,200	35.3	3,027	5.0	14.8	13.3	1.0	1.0	7	18	0
Bumi Serpong Damai	BSDE	BUY	1,135	1,420	25.1	1,578	1.4	10.0	9.9	0.7	0.6	7	0	15
Mitra Adiperkasa	MAPI	BUY	1,935	2,500	29.2	2,109	3.0	14.2	11.6	3.3	2.7	26	15	(1)
Ciputra Development	CTRA	BUY	1,140	1,300	14.0	1,388	2.5	10.5	8.7	1.1	1.0	10	(1)	(10)
HM Sampoerna	HMSP	BUY	880	1,300	47.7	6,722	2.0	12.3	11.7	3.5	3.4	29	(10)	(39.7)
Mayora Indah	MYOR	BUY	2,620	3,000	14.5	3,847	1.2	25.9	22.0	4.0	3.4	17.9	17	17.1

Source: Bloomberg, UOB Kay Hian

Mayora Indah – BUY (Stevanus Juanda)

- **MYOR increased its product prices by 12-18% in 2022; gross margin to improve by 180-480bp yoy in 2023.** Mayora Indah (MYOR) stated that its product ASPs were increased by an average of 15% in 2022 and in the range of 12-18%. As raw material prices are normalising in 2023, MYOR will no longer increase its prices. However, the new and higher prices are likely to remain elevated, which will translate to gross margin improving from 22.2% in 2022 to 25-27% in 2023.
- **ASP increase should overcome the recent rise in wheat and CPO price.** Our sensitivity analysis indicates that every 5% ASP increase will result in NPAT rising by 51.3%; every 5% increase in wheat and CPO prices will cause 2023 NPAT to decline by 6.0% and 4.6% respectively. After increasing ASP by an average of 15% in 2023, we believe 2H23 gross margin could still expand but likely with a lower magnitude.
- **MYOR reported 2Q23 NPAT of Rp494b, rising 41.6% yoy on 594bp gross margin expansion.** The reported 2Q23 NPAT saw strong gross margin improvement of 594bp yoy as raw material prices normalised. Operating margin expanded by 299bp yoy and net margin expanded 261bp yoy. 1H23 NPAT came in at Rp1,219b, rising 86.6% yoy with 1H23 gross margin expanding 585bp yoy.
- **Advertising and promotional expense at 9-11% of sales; lower freight costs as container costs normalise.** MYOR's advertising expenses declined from Rp3.6t in 2021 (13% of sales) to Rp2.65t (8.6% of sales) in 2022. In 2023, MYOR will continue to maintain its advertising and promotion cost at 9-11% of sales. Freight costs rose 19.2% yoy in 2022, but are likely to decrease in 2023 as container costs have normalised and oil prices have declined.
- **2023 NPAT could rise by 44.4% yoy and reach Rp2,593b.** Despite the potential slight pressure from the increase in wheat and CPO prices, we expect MYOR to record a strong yoy growth in NPAT in 2023. We have forecasted 34.8% yoy core NPAT growth in 2023. With 28.1% upside, we maintain BUY on MYOR with target price of Rp3,000.

SHARE PRICE CATALYST

- **Events:** Potential strong results from 3Q23 onwards.
- **Timeline:** 3Q23 results announcement at end-Oct 23.

Bumi Serpong Damai – BUY (Limartha Adhiputra)

- **Meaningful 1H23 marketing sales achievement of Rp4.79t, equivalent to 54% of 2023 marketing sales target of Rp8.8t, up 3% yoy.** The residential segment contributed Rp3.02t, or 63%, to the total 1H23 marketing sales. The commercial segment (including commercial lots, apartments, and shophouses) contributed Rp1.78t, representing 37% of total 1H23 marketing sales. With the meaningful 1H23 achievement, we believe BSDE could achieve its 2023 marketing sales target of Rp8.8t.
- **Expectation of rate cut(s) in late-2H23 and 2024 could lead to an appreciation in BSDE's share price.** The recent decline in inflation numbers in both the US and Indonesia could lead to interest rate cut(s) in 2H23 and 2024. Property names including BSDE could re-rate upwards on the back of an expected rate reduction. Interest rates have peaked and downside is likely. Based on historical performance, BSDE's share price tends to rise whenever interest rates stabilise with expectations of declining.
- **Expect 2023F-24F NPAT to grow 6.8% yoy to Rp2.6t and 0.2% yoy to Rp2.6t respectively.** After strong yoy earnings growth in 1H23, we expect BSDE to continue its earnings growth in 2H23. BSDE usually records higher development revenue in 2H23 as handover of property units usually take place in 2H23. All in all, we maintain our 2023 NPAT forecast at Rp2.6t, up 6.8% yoy and 2024 NPAT forecast at Rp2.6t, up 0.2% yoy.

- **Maintain BUY with a target price of Rp1,420.** We maintain our BUY call for BSDE with a target price of Rp1,420, pegged to its +1SD five-year discount to RNAV of 76.3%. Currently, BSDE is trading at its five-year mean discount to RNAV, which is still attractive. Solid growth in development revenue and NPAT could still come in 2023 as BSDE starts to hand over the 2021-22 property sales.

SHARE PRICE CATALYST

- **Events:** Better 3Q23 marketing sales and NPAT achievement.
- **Timeline:** 3Q23 marketing sales announcement in early-Oct 23.

Ciputra Development – BUY (Limartha Adhiputra)

- **Ciputra Development (CTRA) upgraded its 2023 marketing sales target to Rp9.8t (+19% yoy).** CTRA expects additional growth from all major locations including Medan and Makassar, with a larger contribution from Greater Jakarta and Greater Surabaya. In Jul 23, CTRA further expanded the landed residential portfolio by launching an additional cluster in CitraGarden Serpong. In Aug 23, CTRA had several new projects set to be launched, eg Citra City Sentul, CitraGarden Bintaro and CitraLand Sampali, along with new clusters within CitraLand Gama City Medan and CitraLand Tanjung Morawa. Joint operation and direct ownership projects will contribute 61% and 39% respectively of CTRA's 2023 marketing sales target of Rp9.8t.
- **2H23 marketing sales achievement could be higher than 1H23 as more new products launched.** In Jul 23, CTRA launched a new cluster called Diandre in CitraGarden Serpong. This launch resulted in marketing sales of Rp356b, with a take-up rate of 75%. CTRA plans to launch Citra City Sentul and expects to generate Rp400b in its marketing sales. Another project in Greater Jakarta is CitraGarden Bintaro which is estimated to achieve marketing sales of Rp400b in the first phase. Three projects in Medan, CitraLand Sampali, CitraLand Gama City, and CitraLand Tanjung Morawa are expected to generate marketing sales of Rp450b, Rp130b, and Rp120b respectively.
- **Expect 2023-24 net profit to grow 7.6% yoy to Rp2.0t and 19.6% yoy to Rp2.4t respectively.** 2023-24 revenue could grow on stronger development revenue growth. The high marketing sales in 2022 will translate into stronger development revenue for 2023-24. We expect 2023 revenue to grow 9.8% yoy to Rp10t, of which 78.7% will be development revenue and 21.3% will be recurring revenue. We forecast 2024 revenue at Rp10.8t (+8.2% yoy) with 78.5% contribution from development revenue and 21.5% contribution from recurring revenue.
- **Maintain BUY with a target price of Rp1,300.** This is derived from five-year +1SD discount to 2023 RNAV/share, or at a 66.5% discount to our RNAV. We think CTRA deserves an above-average valuation as it has well-diversified projects in and outside Java that can drive its marketing sales growth in 2023. CTRA is currently trading at near five-year mean discount to 2023 RNAV/share.

SHARE PRICE CATALYST

- **Events:** Better 3Q23 marketing sales and NPAT achievement.
- **Timeline:** 3Q23 marketing sales announcement in early-Oct 23.

Bank Negara Indonesia – BUY (Posmarito Pakpahan)

- **Fundamental improvement in credit risk.** In the last couple of quarters, Bank Negara Indonesia (BBNI) focused on de-risking its balance sheet which led to moderate loan growth compared to other big banks, but also resulted in improving credit risk. Risk Weighted Asset (RWA) density credit risk for loan portfolio declined by 4.6% yoy to 74.7% in Jun 23, which also resulted in an improvement in CAR ratio. BBNI's provision coverage (NPL coverage: 309% and LaR coverage: 47%) is much higher than that in 2019 (NPL coverage: 134% and LaR coverage: 32.3%).

- **Higher CAR, plans to raise DPR to 50%.** Driven by solid earnings as well as improving credit risk, BBNI's tier 1 CAR increased to 19.8% in Jun 23, up from 17.4% in Dec 18. Meanwhile, total CAR stood at 21.6% in Jun 23, up from 18.5% in Dec 18. With improving CAR, BBNI plans to raise its dividend payout ratio (DPR) to 50% from last year's DPR of 40%. With the new DPR, BBNI offers >6% dividend yield at current price.
- **Expect a high single-digit hoh net profit growth in 2H23.** We estimate BBNI to book net profit of Rp11.3t in 2H23, growing 9.5% hoh which will lead to 18% yoy net profit growth in 2023. 2H23 earnings growth will be mainly driven by loan growth which management targets to grow by 7-9% this year. A ramp-up in government spending is expected to support loan growth in 2H23 as the government only spent about 40% of its allocated 2023 budget in 1H23. Furthermore, we expect the bank to book the delayed payment of Kedit Usaha Rakyat's (KUR) subsidy by the government in 2H23, amounting to Rp340b.
- **Maintain BUY with a target price of Rp11,200.** We arrive at 1.3x 2024F P/B by using GGM and assumptions of ROE: 15%, cost of equity: 12.8%, and long-term growth: 5%. BBNI is facing transformation by restructuring its loan portfolio and focusing on digitalisation on its front-end and back-end. Re-rating on valuation will be driven by continued ROAE improvement, for which management targets to reach 18% by 2025. BBNI's ROE has been trending up to 15.4% in 1H23 vs 2.6% in 2020, and is higher than 13.4% in 2019. BBNI is the cheapest stock among the Big Four banks, trading at 1.0x, close to average of its five-year historical P/B.
- **Risks:** Adverse economic development, worsening geopolitical issues, loan growth slowing down.

SHARE PRICE CATALYST

- **Events:** Management targets 7-9% loan growth this year which could translate into loan growth picking up in 2H23.
- **Timeline:** Expecting loan growth to accelerate in 2H23.

HM Sampoerna – BUY (Stevanus Juanda)

- **Excise tax increase of 10% on average for 2023-24.** The Ministry of Finance has decided to increase excise tax for cigarettes by an average of 10% for 2023 and 2024. For unfiltered hand-rolled clove cigarettes, the excise tax jump will be 5% for the largest producers. The excise tax increase for machine-rolled clove cigarettes will be 11.50-11.75% for the largest producers. For non-clove machine-rolled cigarettes, the excise tax hike will be 11-12%. For e-cigarettes, the increase will be 15% in 2023-24.
- **Recovery in purchasing power could bode well for 2023 volume and pricing power.** We think that the potential recovery in purchasing power could bode well for cigarette consumption volume as smokers will trade up their cigarette consumption to the more expensive national brands. We assume that HM Sampoerna's (HMSP) machine-rolled and hand-rolled cigarettes volume will increase by 3% for each segment. An increase in purchasing power will also bode well for pricing as we believe ASP will rise 10% for machine-rolled cigarettes, 12% for non-clove cigarettes, and 5% for hand-rolled cigarettes.
- **Prices have been increasing since 4Q22.** Our channel check indicates that prices have been increasing since 4Q22. According to our source, industry volume declined by 5%. We think profit should rise given that the elasticity of demand is 0.6 for cigarette consumption.
- **Maintain BUY with a target price of Rp1,300.** Our target price is derived using the historical five-year -0.5SD PE of 26.3x applied to 2023F EPS. With 42.9% upside from the current level, we maintain BUY on HMSP with a target price of Rp1,300.

SHARE PRICE CATALYST

- **Events:** 2024 excise tax announcement in late-2H23.
- **Timeline:** Announcement of strong 3Q23 results.

Semen Indonesia – BUY (Limartha Adhiputra)

- **Cement demand continues to show an uptrend in 1H23.** We saw an improvement in cement demand growth during 1H23. The cement demand contraction improved to -1.1% yoy in Jun 23 from -6.7% yoy in May 23. In Jul 23, SMGR's cement sales volume indicated a positive growth and we expect the positive trend to continue in 2H23. SMGR expects more cement demand to come from infrastructure projects in Sumatra and IKN constructions in 2H23.
- **Margin will continue to expand in 2H23.** SMGR's 1H23 net profit margin improved slightly to 5.1% vs to 5.0% in 1H22. In 2H23, SMGR believes its profit margin could continue to expand as the positive growth trend in cement sales volume is improving with minimum risk from coal input cost. We expect SMGR to continue delivering a higher profit margin of 7.7% in 2023 as the risk of coal price fluctuations has been minimised by securing 100% of its coal supply at DMO prices.
- **Expect SMGR's 2023 net profit to grow 30.9% yoy.** We maintain SMGR's 2023 revenue at Rp40.2t, up 10.5% yoy from Rp36.4t in 2022 with EBITDA expected to grow 14.5% yoy to Rp9.05t. 2023 NPAT is forecasted to grow 30.9% yoy to Rp3.1t vs Rp2.4t in 2022. We project 2023 sales volume to increase 11% yoy to 40.9m tonnes as SMGR has new strategies to tackle the fierce competition and oversupply conditions in the cement market.
- **Maintain BUY with a target price of Rp9,200.** We still believe SMGR can record higher NPAT and margin growth in 2023 as it has secured 100% of its coal at DMO prices. We base our target price on the stock's -0.5SD to its five-year 2023 forward EV/EBITDA of 7.9x. Currently, SMGR is trading at -1.5SD to its five-year EV/EBITDA, which is still very attractive.

SHARE PRICE CATALYST

- **Events:** Potentially stronger sales volume, margin expansion, and higher NPAT achievement in 2H23.
- **Timeline:** 3Q23 results announcement in end-Oct 23.

Mitra Adiperkasa – BUY (Stevanus Juanda)

- **Over 150 profitable and exclusive brands.** A key factor in Mitra Adiperkasa's (MAPI) success is its >150 exclusive brands that are profitable. This exclusivity creates barriers of entry to competitors as well as better margins. Only Nike, Sephora (60% of products), Puma and Adidas (which contributed about 4.7% of MAPI's sales) are non-exclusive brands. MAPI has worked hard to rationalise its brands portfolio over the past few years, and non-performing brands have been divested.
- **Key to higher margins lies in exclusive brands.** MAP Active's (MAPA) net margin of 9.0% is much higher than its regional peers' 4.5% and investors want to know if there is a risk of future margin erosion. MAPI stated that about 90% of its brands are exclusive to it in Indonesia, and only Nike, Adidas, Puma and Sephora are not exclusive. The exclusivity should translate to barriers of entry to competitors. MAPA's top five brands are Skechers, Converse, Reebok, New Balance and Nike, of which three are exclusive to MAPI.

- **Exclusivity of brands extended to regional markets.** A key competitive advantage of MAPI is the exclusivity of its brands in Indonesia which creates barriers of entry and better margins earned compared with its regional peers. Fortunately, this exclusivity has also extended into its international operations such as Vietnam. In Vietnam, all Inditex Group (Zara, Massimo Dutti, Pull & Bear, etc), Birkenstock, Converse, Champion and Digimap brands are exclusive. In the Philippines, the exclusive brands are Converse, New Balance, Haddad, Airwalk, Hoka and Fitflop. In Singapore and Malaysia, JVs are formed with Converse and Reebok.
- **All business segments except department stores have recorded higher sales than pre-pandemic levels.** With the exception of department stores, all other business segments (fashion, sportswear, F&B and Digimap) have recorded sales higher than 2019's levels. This should be viewed positively as recovery in GDP growth will continue to support MAPI's sales going forward.
- **Maintain BUY with a target price of Rp2,500,** derived using historical average five-year PE applied to average 2023 and 2024 EPS. Given a 26.3% upside from the current level, we maintain BUY on MAPI.

SHARE PRICE CATALYST

- **Events:** Strong profit growth momentum from 3Q23 onwards and acquisition of new brands.
- **Timeline:** Announcement of results in 3Q23.

TRADERS' CORNER



Source: Amibroker

Bumi Resources (BUMI IJ)

Technical BUY with 7% potential return

Resistance: Rp146, Rp153

Support: Rp135, Rp127

Stop-loss: Rp134

Share price closed higher and formed a neutral candlestick. That said, momentum is looking more positive; hence, we expect more upside pressure to take place and challenge the resistance at Rp146 and Rp153. Technical indicator RSI is sloping upwards and above its centre line, while the MACD is relatively flattish for now. Buy at Rp140 and take profit at Rp150.

Approximate timeframe: 2-4 weeks.



Source: Amibroker

Aneka Tambang (ANTM IJ)

Technical BUY with 7.5% potential return

Resistance: Rp2,060, Rp2,150

Support: Rp1,925, Rp1,895

Stop-loss: Rp1,920

Share price closed lower but formed a bullish candlestick. The price formed a bullish reversal pattern; hence, we see potential for more rebounds to take place and challenge the resistance at Rp2,060 and Rp2,150. Technical indicator RSI is sloping downwards and under its centre line, while the MACD is relatively flattish for now. Buy at Rp1,950 and take profit at Rp2,100.

Approximate timeframe: 2-4 weeks.

ANALYST(S)

Maskun Ramli, CFTE

+6221 2993 3915

maskunramli@uobkayhian.com

Disclosures/Disclaimers

This report is prepared by PT UOB Kay Hian Sekuritas ("PT UOBKH"), a licensed broker dealer registered in the Republic of Indonesia and a member of the Indonesia Stock Exchange ("IDX")

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of PT UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as PT UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject PT UOBKH and its associates and its officers, employees and representatives to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by PT UOBKH to be reliable. However, PT UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and PT UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information PT UOBKH and its associate may have issued other reports expressing views different from the Information and all views expressed in all reports of PT UOBKH and its connected persons are subject to change without notice. PT UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) PT UOBKH, its associates and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) PT UOBKH, its associate and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of PT UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) PT UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report is prepared by PT UOBKH, a company authorized, as noted above, to engage in securities activities in Indonesia. PT UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by PT UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from PT UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through PT UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Analyst Certification/Regulation AC

Each research analyst of PT UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of PT UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including PT UOBKH total revenues, a portion of which are generated from PT UOBKH business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2023, PT UOB Kay Hian Sekuritas. All rights reserved.

<http://research.uobkayhian.com>